Jean Pierre Routy

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. ncbi Comparison of clinical features of acute HIV-1 infection in patients infected sexually or through injection drug use. The Investigators of the Québec Primary HIV Infection Study
    J P Routy
    McGill University Health Centre, McGill AIDS Centre, and McGill University, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 24:425-32. 2000
  2. ncbi Valproic acid: a potential role in treating latent HIV infection
    Jean-Pierre Routy
    Division of Hematology, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec H3A 1A1, Canada
    Lancet 366:523-4. 2005
  3. ncbi Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy
    Jean Pierre Routy
    Immunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, Montreal, QC, Canada
    Clin Immunol 134:140-7. 2010
  4. ncbi Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
    Jean Pierre Routy
    Immunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    AIDS 18:2305-12. 2004
  5. ncbi Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection
    Jean Pierre Routy
    Argos Therapeutics Inc, Durham, NC, USA
    Immunotherapy 2:467-76. 2010
  6. ncbi Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study
    Alexandre Iannello
    Laboratory of Innate Immunity, Centre Hospitalier Universitaire Sainte Justine Research Center, University of Montreal, Montreal, Canada
    J Immunol 184:114-26. 2010
  7. ncbi IL-21 enhances NK cell functions and survival in healthy and HIV-infected patients with minimal stimulation of viral replication
    Alexandre Iannello
    Laboratory of Innate Immunity, CHU Sainte Justine Research Center, McGill University, Montreal, Canada
    J Leukoc Biol 87:857-67. 2010
  8. ncbi Changes in function of HIV-specific T-cell responses with increasing time from infection
    Michel L Ndongala
    Research Institute of the McGill University Health Center, Montreal, Quebec, Canada
    Viral Immunol 23:159-68. 2010
  9. ncbi Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: correlation of these functional T cell subsets with markers of disease progression
    Yoav Peretz
    Research Institute of the McGill University Health Center, Montreal General Hospital, Montreal, Quebec, Canada
    Clin Immunol 124:57-68. 2007
  10. ncbi High rates of forward transmission events after acute/early HIV-1 infection
    Bluma G Brenner
    McGill AIDS Centre Jewish General Hospital, Montreal, Canada
    J Infect Dis 195:951-9. 2007

Detail Information

Publications87

  1. ncbi Comparison of clinical features of acute HIV-1 infection in patients infected sexually or through injection drug use. The Investigators of the Québec Primary HIV Infection Study
    J P Routy
    McGill University Health Centre, McGill AIDS Centre, and McGill University, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 24:425-32. 2000
    ..Our study results clearly indicate that health care workers can expect similar clinical presentation of AHI in MSM and in IDUs despite the different routes of infection...
  2. ncbi Valproic acid: a potential role in treating latent HIV infection
    Jean-Pierre Routy
    Division of Hematology, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec H3A 1A1, Canada
    Lancet 366:523-4. 2005
  3. ncbi Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy
    Jean Pierre Routy
    Immunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, Montreal, QC, Canada
    Clin Immunol 134:140-7. 2010
    ..No evidence of autoimmunity, changes in viral load, or significant changes in absolute CD4(+) and CD8(+) T cell counts were observed. This pilot study supports the further clinical investigation of AGS-004...
  4. ncbi Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
    Jean Pierre Routy
    Immunodeficiency Service and Division of Hematology, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    AIDS 18:2305-12. 2004
    ..A study of chronically infected (CI) patients, who represent potential HIV-1 transmitters, was carried out in order to ascertain biological factors associated with this trend change...
  5. ncbi Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection
    Jean Pierre Routy
    Argos Therapeutics Inc, Durham, NC, USA
    Immunotherapy 2:467-76. 2010
    ..Based on the encouraging immunogenicity and tolerance observed in a Phase I study, a Phase II study has been initiated with good tolerance and partial viral control. A second Phase II placebo-controlled study is about to initiate...
  6. ncbi Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study
    Alexandre Iannello
    Laboratory of Innate Immunity, Centre Hospitalier Universitaire Sainte Justine Research Center, University of Montreal, Montreal, Canada
    J Immunol 184:114-26. 2010
    ..Together, our results suggest that serum IL-21 concentrations may serve as a useful biomarker for monitoring HIV disease progression and the cytokine may be considered for immunotherapy in HIV-infected patients...
  7. ncbi IL-21 enhances NK cell functions and survival in healthy and HIV-infected patients with minimal stimulation of viral replication
    Alexandre Iannello
    Laboratory of Innate Immunity, CHU Sainte Justine Research Center, McGill University, Montreal, Canada
    J Leukoc Biol 87:857-67. 2010
    ..These data suggest that IL-21 may serve as a valuable therapeutic tool for enhancing NK cell responses and inhibiting viral replication in HIV-infected patients...
  8. ncbi Changes in function of HIV-specific T-cell responses with increasing time from infection
    Michel L Ndongala
    Research Institute of the McGill University Health Center, Montreal, Quebec, Canada
    Viral Immunol 23:159-68. 2010
    ..By the second year of infection there was a significant difference in these functions compared to those assessed within 6 mo...
  9. ncbi Functional T cell subsets contribute differentially to HIV peptide-specific responses within infected individuals: correlation of these functional T cell subsets with markers of disease progression
    Yoav Peretz
    Research Institute of the McGill University Health Center, Montreal General Hospital, Montreal, Quebec, Canada
    Clin Immunol 124:57-68. 2007
    ....
  10. ncbi High rates of forward transmission events after acute/early HIV-1 infection
    Bluma G Brenner
    McGill AIDS Centre Jewish General Hospital, Montreal, Canada
    J Infect Dis 195:951-9. 2007
    ..A population-based phylogenetic approach was used to characterize human immunodeficiency virus (HIV)-transmission dynamics in Quebec...
  11. ncbi HIV-1 causes an imbalance in the production of interleukin-18 and its natural antagonist in HIV-infected individuals: implications for enhanced viral replication
    Alexandre Iannello
    Laboratory of Innate Immunity, Centre Hospitalier Universitaire Sainte Justine Research Center, Montreal, Quebec, Canada
    J Infect Dis 201:608-17. 2010
    ..However, nothing is known concerning the regulation of IL-18-binding protein (IL-18BP), which neutralizes IL-18 in vivo. This issue is addressed in the present study...
  12. ncbi Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection
    Elias A Said
    Centre de recherche du Centre hospitalier de l Université de Montréal CRCHUM, Hôpital St Luc, Montreal, Quebec, Canada
    Nat Med 16:452-9. 2010
    ..We describe a new function for PD-1 whereby microbial products inhibit T cell expansion and function by upregulating PD-1 levels and IL-10 production by monocytes after binding of PD-1 by PD-L1...
  13. ncbi Decreased levels of circulating IL-21 in HIV-infected AIDS patients: correlation with CD4+ T-cell counts
    Alexandre Iannello
    Laboratory of Innate Immunity, Ste Justine Hospital Research Center, Montreal, Quebec, Canada
    Viral Immunol 21:385-8. 2008
    ..These data suggest that the cytokine levels could act as a valuable biomarker for the progression of AIDS...
  14. ncbi Potential role of IL-18 in the immunopathogenesis of AIDS, HIV-associated lipodystrophy and related clinical conditions
    Alexandre Iannello
    Laboratory of Innate Immunity, CHU Sainte Justine Research Center Department of Microbiology and Immunology, University of Montreal, 3175 chemin de la Cote Sainte Catherine, Montreal, Quebec H3T1C5, Canada
    Curr HIV Res 8:147-64. 2010
    ..The cytokine may prove to be a useful target for therapeutic intervention in these patients...
  15. ncbi CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction
    Yoav Peretz
    Caprion ImmuneCarta Services, Montreal, Quebec, Canada
    PLoS Pathog 8:e1002840. 2012
    ....
  16. ncbi Transmission networks of drug resistance acquired in primary/early stage HIV infection
    Bluma G Brenner
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    AIDS 22:2509-15. 2008
    ..In Quebec, half of PHIs represent clustered transmission events. This study ascertained the cumulative implications of clustering on onward transmission of drug resistance...
  17. ncbi A dual color ELISPOT method for the simultaneous detection of IL-2 and IFN-gamma HIV-specific immune responses
    Salix Boulet
    Research Institute of the McGill University Health Center, Montreal, Canada
    J Immunol Methods 320:18-29. 2007
    ..Features of this assay such as high throughput, cell number requirement and cytokine choice should make this assay a valuable tool for screening for HIV-specific immune responses in several clinically relevant settings...
  18. ncbi The colocalization potential of HIV-specific CD8+ and CD4+ T-cells is mediated by integrin β7 but not CCR6 and regulated by retinoic acid
    Vanessa Sue Wacleche
    Department of Microbiology and Immunology, Universite de Montreal, Montreal, Quebec, Canada
    PLoS ONE 7:e32964. 2012
    ....
  19. ncbi Peripheral blood CCR4+CCR6+ and CXCR3+CCR6+CD4+ T cells are highly permissive to HIV-1 infection
    Annie Gosselin
    Department of Microbiology and Immunology, Universite de Montreal, Montreal, Quebec, Canada
    J Immunol 184:1604-16. 2010
    ..It is necessary that new therapeutic strategies against HIV interfere with viral replication/persistence in discrete CCR6(+) T cell subsets...
  20. ncbi Predictive value of interleukin-7 levels for virological response to treatment in HIV-1-infected children
    Mohamed Rachid Boulassel
    Division of Hematology, Immunodeficiency Service, McGill University Health Centre, Quebec, Canada
    Viral Immunol 20:649-56. 2007
    ..Collectively, these results indicate that IL-7 levels at baseline are predictive of virological but not immunological response to ART in children infected with HIV-1...
  21. ncbi Relative contribution of HIV-specific functional lymphocyte subsets restricted by protective and non-protective HLA alleles
    Yoav Peretz
    National Immune Monitoring Laboratory NIML, Genome Quebec, Montreal, Quebec, Canada
    Viral Immunol 24:189-98. 2011
    ..HLA haplotypes influence the relative functional composition of HIV-specific responses...
  22. ncbi Memory CCR6+CD4+ T cells are preferential targets for productive HIV type 1 infection regardless of their expression of integrin β7
    Patricia Monteiro
    Department of Microbiology and Immunology, University of Montreal, Montreal, H3C 3J7 Quebec, Canada
    J Immunol 186:4618-30. 2011
    ....
  23. ncbi Transcription factor FOXO3a controls the persistence of memory CD4(+) T cells during HIV infection
    Julien van Grevenynghe
    Laboratoire d Immunologie, Centre de Recherche, Hopital Saint Luc, Centre Hospitalier de l Universite de Montreal, 264 Boulevard Rene Levesque Est, Montreal, Quebec H2X 1P1, Canada
    Nat Med 14:266-74. 2008
    ..The crucial role of FOXO3a in the survival of memory cells will help shed light on the underlying immunological mechanisms that control viral replication in EC subjects...
  24. ncbi Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells
    Alexandre Iannello
    Department of Microbiology and Immunology, Laboratory of Innate Immunity, CHU Sainte Justine Research Center, University of Montreal, Montreal, Quebec, Canada
    J Virol 83:5999-6010. 2009
    ..These results suggest that increased IL-18 concentrations present in the circulation of HIV-infected persons contribute to the immunopathogenesis of AIDS by altering NK cell homeostasis...
  25. ncbi CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy
    Mohamed Rachid Boulassel
    Division of Hematology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
    J Clin Virol 53:29-32. 2012
    ..However, the relevance of reservoir level while on efficient antiretroviral therapy (ART) is still unknown...
  26. ncbi Slow disease progression and robust therapy-mediated CD4+ T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection
    Marie Lise Dion
    Laboratoire d Immunologie, Centre de Recherches du Centre Hospitalier de l Université de Montréal CR CHUM, Hopital Saint Luc, Montreal, QC, Canada
    Blood 109:2912-20. 2007
    ..Overall, we demonstrate that efficient thymopoiesis is key in the natural maintenance and in therapy-mediated recovery of naive and total CD4+ T cells...
  27. ncbi Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
    Lydie Trautmann
    Laboratoire d Immunologie, Centre de Recherche du Centre Hospitalier de l Université de Montréal CR CHUM Saint Luc, 264 Rene Levesque Est, Montreal, Québec H2X1P1, Canada
    Nat Med 12:1198-202. 2006
    ..The accumulation of HIV-specific dysfunctional CD8(+) T cells in the infected host could prevent the renewal of a functionally competent HIV-specific CD8(+) repertoire...
  28. ncbi Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57
    Philomena Kamya
    Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    J Virol 85:5949-60. 2011
    ..The protective effect of HLA-B*57 on slow progression to AIDS and low VL may be mediated through its interaction with KIR3DL1 alleles to educate NK cells for potent activity upon stimulation...
  29. ncbi HIV infection affects blood myeloid dendritic cells after successful therapy and despite nonprogressing clinical disease
    Julie Fontaine
    Laboratoire d Immunogénétique, Centre de recherche du Centre Hospitalier de l Universite de Montreal, Département de Microbiologie et Immunologie de l Université de Montréal, Montreal, Quebec, Canada
    J Infect Dis 199:1007-18. 2009
    ..pDC levels followed the pattern of CD4+ T cell fluctuations. These findings provide evidence for an ongoing process affecting mDCs after successful ART and despite nonprogressing clinical disease following HIV infection...
  30. ncbi Mind the gap: lack of association between KIR3DL1*004/HLA‐Bw4-induced natural killer cell function and protection from HIV infection
    Matthew S Parsons
    Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    J Infect Dis 202:S356-60. 2010
    ..Thus, despite its ability to license NK cells, KIR3DL1*004/HLA‐Bw4 is not associated with a reduced risk of infection...
  31. ncbi Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV infection
    Galit Alter
    McGill University Health Centre, Montreal, Quebec, Canada
    J Infect Dis 185:755-65. 2002
    ..02, paired t test). Maximal breadth of the HIV gene product reactivity was achieved within 2 months of exposure for Nef-specific responses and by 4 months of exposure for responses directed to Env, Gag, and reverse transcriptase...
  32. ncbi Immunophenotypic patterns of CD8+ T cell subsets expressing CD8alphaalpha and IL-7Ralpha in viremic, aviremic and slow progressor HIV-1-infected subjects
    Mohamed Rachid Boulassel
    Immunodeficiency Service, Montreal Chest Institute, McGill University Health Centre, Montreal, Quebec, Canada
    Clin Immunol 124:149-57. 2007
    ....
  33. ncbi The duration of exposure to HIV modulates the breadth and the magnitude of HIV-specific memory CD4+ T cells
    Souheil Antoine Younes
    Laboratoire d Immunologie, Departement de Microbiologie et Immunologie, Universite de Montreal, Montreal, Quebec, Canada
    J Immunol 178:788-97. 2007
    ....
  34. ncbi Autologous HIV-1 Clade-B Nef Peptides Elicit Increased Frequency, Breadth and Function of CD8(+) T-Cells Compared to Consensus Peptides
    Mehrnoosh Doroudchi
    Laboratoire d Immunologie, Centre de Recherche du Centre Hospitalier de l Université de Montréal CR CHUM Saint Luc, Montreal, Quebec, Canada Laboratoire d Immunologie, Département de Microbiologie et d Immunologie, Universite de Montreal, Quebec, Canada INSERM U743, CR CHUM, Universite de Montreal, Montreal, Quebec, Canada Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
    PLoS ONE 7:e49562. 2012
    ..To determine the function and phenotype of CD8(+) T-cells targeting consensus and autologous sequences of entire HIV-1 Nef protein...
  35. ncbi Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals
    Salix Boulet
    Research Institute of the McGill University Health Centre, Montreal, Canada
    AIDS 22:595-9. 2008
    ....
  36. ncbi HIV Gag p24 specific responses secreting IFN-gamma and/or IL-2 in treatment-naïve individuals in acute infection early disease (AIED) are associated with low viral load
    Michel L Ndongala
    Research Institute of the McGill University Health Center, Montreal General Hospital, Quebec, Canada
    Clin Immunol 131:277-87. 2009
    ..Therefore the early appearance of broader and more intense Gag-p24-specific responses may be a determinant of subsequent VL...
  37. ncbi The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90
    Irina Tcherepanova
    Research and Development Department, Argos Therapeutics Inc, Durham, NC, USA
    PLoS ONE 4:e5853. 2009
    ..Consistent with this idea are reports that defects in the C-terminus of Vpr are associated with long-term non-progression...
  38. ncbi T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers
    Philomena Kamya
    Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada
    AIDS Res Ther 8:20. 2011
    ..abstract:..
  39. ncbi Forced expression of HLA-DM at the surface of dendritic cells increases loading of synthetic peptides on MHC class II molecules and modulates T cell responses
    Abdul Mohammad Pezeshki
    Laboratoire d Immunologie Moléculaire, Departement de Microbiologie et Immunologie, Universite de Montreal, Montreal, Quebec H3C 3J7, Canada
    J Immunol 187:74-81. 2011
    ..Taken together, our results suggest that the overexpression of HLA-DMY at the plasma membrane of DCs may improve quantitatively, but also qualitatively, the presentation of CD4 T cell epitopes in cellular vaccine therapies for cancer...
  40. ncbi HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing
    Angelique Bellemare-Pelletier
    Laboratoire d Immunologie Moléculaire, Departement de Microbiologie et Immunologie, Universite de Montreal, CP 6128, Quebec, Canada
    J Leukoc Biol 78:95-105. 2005
    ..These results show that transduced DO modulates antigen presentation in human mature MoDC, evoking the possible use of this chaperone for immunotherapy...
  41. ncbi HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
    Nicolas Chomont
    Laboratoire d Immunologie, Centre de Recherche du Centre Hospitalier de l Université de Montréal Saint Luc, Montreal, Quebec, Canada
    Nat Med 15:893-900. 2009
    ....
  42. ncbi The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation
    Claudia Penafuerte
    Department of Medicine, Division of Experimental Medicine, McGill University, Canada
    Cancer Res 69:9020-8. 2009
    ..In conclusion, hGIFT2 fusokine possesses unique biochemical properties distinct from IL-2 and GM-CSF, constitutes a novel and potent tool for ex vivo NK cell activation and maturation, and may be of use for cancer cell immunotherapy...
  43. ncbi Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes
    Laïla Aïcha Hanafi
    Research Centre, Centre Hospitalier de l Université de Montréal CRCHUM Hôpital Notre Dame, Université de Montréal and Institut du Cancer de Montréal, Montreal, Quebec, Canada
    Vaccine 28:5617-26. 2010
    ..Results suggest that potexvirus VLPs are an attractive vaccine platform for inducing a CTL response...
  44. ncbi Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33, and 35
    Gilbert Cornut
    Centre de Recherche and Département de Microbiologie Infectiologie, Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
    J Med Virol 82:1168-78. 2010
    ..dN/dS ratios were below 1.0 in extra-loop and intra-loop regions, but they were lower in extra-loop regions. These results suggest that sequences within and outside the hypervariable loops of L1 were under selective constraint...
  45. ncbi Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance
    Jessica Godin-Ethier
    Research Centre, Centre Hospitalier de l Université de Montréal Hôpital Notre Dame, Université de Montréal and Institut du Cancer de Montréal, Montreal, Quebec, Canada
    J Immunol 183:7752-60. 2009
    ..These findings demonstrate complex control of immune activity within tumors. Future immune therapeutic interventions should thus include strategies to counteract these negative mechanisms...
  46. ncbi Clonotype and repertoire changes drive the functional improvement of HIV-specific CD8 T cell populations under conditions of limited antigenic stimulation
    Loury Janbazian
    Laboratory of Immunology, Department of Microbiology and Immunology, University of Montreal, Montreal, Quebec H2X 1P1, Canada
    J Immunol 188:1156-67. 2012
    ....
  47. ncbi Persistence of high levels of blood soluble human leukocyte antigen-G is associated with rapid progression of HIV infection
    Julie Lajoie
    Centre de recherche du Centre Hospitalier de l Universite de Montreal, Quebec, Canada
    AIDS 23:1437-40. 2009
    ....
  48. ncbi Near full-length genomic analysis of a novel subtype A1/C recombinant HIV type 1 isolate from Canada
    Michel Ntemgwa
    McGill University AIDS Centre, Lady Davis Institute Jewish General Hospital, Montreal, Quebec H3T 1E2, Canada
    AIDS Res Hum Retroviruses 24:655-9. 2008
    ..This is the first report of a recombinant involving subtypes A1 and C in Canada, the epidemiologic significance of which is not yet known...
  49. ncbi Long-term immunosuppression with anti-CD25 monoclonal antibodies in heart transplant patients with chronic kidney disease
    Marcelo Cantarovich
    Multiorgan Transplant Program, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada
    J Heart Lung Transplant 28:912-8. 2009
    ..Current strategies include dose reduction or conversion from calcineurin inhibitors (CNIs) to either mycophenolate mofetil and/or rapamycin, with variable results and side-effect profiles...
  50. ncbi Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia
    Naoufel Azizi
    Laboratoire de Virologie Moleculaire, Centre de recherche du Centre Hospitalier de l Universite de Montreal, Montreal, Quebec, Canada
    J Gen Virol 89:1716-28. 2008
    ..24) or CIN-1 (5 of 14, P=0.50). HPV-16 E2 polymorphism was a significant factor that influenced measures of HPV-16 integrated viral load...
  51. ncbi Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series
    Alain Bestawros
    Division of Internal Medicine, Montreal General Hospital and McGill University, Montreal, Canada
    Am J Hematol 83:508-11. 2008
    ..Further studies will be needed to assess the efficacy and safety of such an approach, and to identify risk factors predictive of long-term tolerance in HIV patients with different degrees of immunosuppression...
  52. ncbi Regulatory T Cells in HIV Infection: Can Immunotherapy Regulate the Regulator?
    Mohammad Ali Jenabian
    Chronic Viral Illnesses Service, McGill University Health Centre, 3650 St Urbain Street, Montreal, QC, Canada H2X 2P4 Research Institute, McGill University Health Centre, Montreal, QC, Canada H3H 2R9
    Clin Dev Immunol 2012:908314. 2012
    ..However, such approaches require a better understanding of the time upon infection when interfering with Treg function may not cause a deleterious state of hyperimmune activation...
  53. ncbi Role of interleukin-18 in the development and pathogenesis of AIDS
    Alexandre Iannello
    Laboratory of Innate Immunity, CHU Sainte Justine Research Center, University of Montreal, Montreal, Quebec, Canada
    AIDS Rev 11:115-25. 2009
    ..It may delay AIDS progression and improve the immune status of infected persons. The best way to achieve this goal may be using exogenous interleukin-18 binding protein...
  54. ncbi Effects of drug resistance on viral load in patients failing antiretroviral therapy
    N Machouf
    Clinique Médicale l Actuel, Montreal, Quebec, Canada
    J Med Virol 78:608-13. 2006
    ..Together, these findings suggest that long-term maintenance of a sub-optimal antiretroviral regimen may have deleterious consequences for the patient...
  55. ncbi Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection
    G Alter
    McGill University Health Center, Montreal, Quebec, Canada
    J Immunol 171:477-88. 2003
    ..Our results show that HIV-specific immunity can be preserved even if HAART is initiated beyond the acute phase of infection...
  56. ncbi Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients
    D Turner
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    New Microbiol 27:31-9. 2004
    ..Collectively, these factors might explain the residual antiviral effect and clinical benefit observed with continued use of 3TC in combination therapy regimens following the emergence of M184V...
  57. ncbi Prevalence, clearance, and incidence of anal human papillomavirus infection in HIV-infected men: the HIPVIRG cohort study
    Alexandra de Pokomandy
    Departement De Microbiologie et Infectiologie, Hôpital Notre Dame du Centre Hospitalier de l Université de Montréal, département de médecine familiale, Faculte de Medecine, Universite de Montreal, Montreal, Quebec, Canada
    J Infect Dis 199:965-73. 2009
    ..This study was conducted to better understand the natural history of type-specific HPV infection in the anus...
  58. ncbi Influence of RANTES, SDF-1 and TGF-beta levels on the value of interleukin-7 as a predictor of virological response in HIV-1-infected patients receiving double boosted protease inhibitor-based therapy
    M R Boulassel
    Immunodeficiency Service, Montreal Chest Institute, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
    HIV Med 6:268-77. 2005
    ..Furthermore, they indicate that RANTES, SDF-1 or TGF-beta levels do not explain the predictor value of IL-7 in patients receiving ART...
  59. ncbi Persistent human immunodeficiency virus-1 antigenaemia affects the expression of interleukin-7Ralpha on central and effector memory CD4+ and CD8+ T cell subsets
    F Mercier
    Immunodeficiency Service, Montreal Chest Institute, Montreal, Quebec, Canada
    Clin Exp Immunol 152:72-80. 2008
    ..Collectively, these results provide further insight on the role of unsuppressed viral load in disrupting the IL-7/IL-7Ralpha system and contributing to HIV-1 disease progression...
  60. ncbi Interleukin-7 levels may predict virological response in advanced HIV-1-infected patients receiving lopinavir/ritonavir-based therapy
    M R Boulassel
    Immunodeficiency Service Division of Hematology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
    HIV Med 4:315-20. 2003
    ..CONCLUSIONS: These findings are consistent with regulation of T-cell recovery by IL-7, and suggest that IL-7 measurements might be used to predict virological response...
  61. ncbi Plasmapheresis in the treatment of an acute pancreatitis due to protease inhibitor-induced hypertriglyceridemia
    J P Routy
    Division of Hematology, McGill University Health Centre, Montreal, Quebec, USA
    J Clin Apher 16:157-9. 2001
    ..To our knowledge, this is the first case of pancreatitis due to a PI-induced hyperlipidemia in a HIV-patient treated with plasmapheresis in an acute setting...
  62. ncbi Improvement of HIV-specific immunity in HIV-infected twins treated with highly active antiretroviral therapy, interleukin 2, and syngeneic adoptively transferred cells
    C M Tsoukas
    Immunodeficiency Treatment Centre, McGill University Health Centre, Montreal General Hospital, Montreal, Quebec, Canada
    AIDS Res Hum Retroviruses 17:887-900. 2001
    ....
  63. ncbi Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection
    Bluma G Brenner
    McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec, Canada
    J Virol 76:1753-61. 2002
    ..These results indicate that MDR viruses that are generated following PHI can establish persistent infections as dominant quasispecies despite their impaired replicative competence...
  64. ncbi Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L
    Jacob Bukczynski
    Department of Immunology, University of Toronto, Toronto, Canada
    J Immunol 175:6378-89. 2005
    ..Taken together, these data suggest that 4-1BBL and B7.1 have additive or synergistic effects on HIV-specific CD8 T cell responses and represent a promising combination for therapeutic vaccination for HIV...
  65. ncbi Antiretroviral-drug resistance among patients recently infected with HIV
    Susan J Little
    Antiviral Research Center, Department of Medicine, University of California San Diego, San Diego 92103, USA
    N Engl J Med 347:385-94. 2002
    ..Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estimated at 1 to 11 percent...
  66. ncbi HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity
    Souheil-Antoine Younes
    , , 2900 Edouard-Montpetit Boulevard, , Canada
    J Exp Med 198:1909-22. 2003
    ..Our data favor a model whereby competent HIV-specific Tcm continuously arise in small numbers but under persistent antigenemia are rapidly induced to differentiate into IFN-gamma only-producing cells that lack self-renewal capacity...
  67. ncbi Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection
    Andrew J Leigh Brown
    University of Edinburgh, Edinburgh, Scotland
    J Virol 78:2242-6. 2004
    ..This supports the view that variation in PR function is directly responsible for variation in fitness among strains in primary infection...
  68. ncbi Variability in the PR and RT genes of HIV-1 isolated from recently infected subjects
    Dan Turner
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, , , Canada
    Antivir Chem Chemother 15:255-9. 2004
    ..In conclusion, variability in the RT and PR genes of viruses from recently infected patients has increased over time in a manner that is independent of variability attributable to HIV drug resistance...
  69. ncbi A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection
    Salix Boulet
    Research Institute of the McGill University Health Centre, Canada
    AIDS 22:1487-91. 2008
    ..We questioned whether this allele combination could also influence resistance to infection...
  70. ncbi Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles
    Hendrik Streeck
    Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02129, USA
    J Virol 81:7725-31. 2007
    ....
  71. ncbi Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance
    Lin Liu
    University of California San Diego, La Jolla, California 92093 0679, USA
    AIDS 22:835-9. 2008
    ..We compared eight genotypic interpretation methods to determine whether the method used would affect the rates of reported transmitted drug resistance...
  72. ncbi Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients
    Graham H R Smith
    Immunodeficiency Service, Montreal Chest Institute, McGill University Health Centre, 3650 rue St-Urbain, Montreal, Quebec, H2X 2P4 Canada
    HIV Clin Trials 6:63-72. 2005
    ..CONCLUSION: These findings suggest that baseline PI resistance and saquinavir concentration were associated with virologic response and should be considered when planning salvage therapy...
  73. ncbi Characterization of humoral and cell-mediated immune responses directed against hepatitis C virus F protein in subjects co-infected with hepatitis C virus and HIV-1
    Myriam Troesch
    , Centre de Recherche, , Montreal, Quebec, Canada
    AIDS 19:775-84. 2005
    ....
  74. ncbi Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection
    Bluma Brenner
    McGill University AIDS Centre, Jewish General Hospital and McGill University Health Centre, Montreal, Quebec, Canada
    AIDS 18:1653-60. 2004
    ..CONCLUSIONS: Genotypic analysis in PHI may identify superinfection and MDR infections that represent important determinants of virological and treatment outcome...
  75. ncbi Assessment of longitudinal changes in HIV-specific effector activity in subjects undergoing untreated primary HIV infection
    Galit Alter
    McGill University Health Centre, Montreal, Quebec, Canada
    AIDS 18:1979-89. 2004
    ..CONCLUSION: Given that a significant relationship existed between the magnitude of the HIV-specific response and viral load, it is likely that these effector cell expansions and contractions are driven by changes in antigen load...
  76. ncbi Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection
    Dan Turner
    McGill University AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada
    J Acquir Immune Defic Syndr 37:1627-31. 2004
    ..05). These findings suggest that both decreased viremia and viral fitness in the case of M184V-containing HIV-1 variants may impact on viral transmissibility...
  77. ncbi Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity
    Jason D Barbour
    Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 20:2123-5. 2006
    ..Viral polRC was measured before starting ART in all subjects. We examined 243 individuals for a median 260 days after initiating ART. Low baseline polRC was associated with greater CD4 T-cell gains independent of virological responses...
  78. ncbi 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells
    Chao Wang
    Department of Immunology, University of Toronto, Toronto, Canada
    J Immunol 179:8252-63. 2007
    ..These studies identify 4-1BBL as a critical component in therapeutic strategies aimed at improving CD8 T cell function...
  79. ncbi Abacavir sulfate and mania in HIV
    Marie Josée Brouilette
    Am J Psychiatry 164:979-80. 2007
  80. ncbi HIV infection rapidly induces and maintains a substantial suppression of thymocyte proliferation
    Marie-Lise Dion
    Laboratoire d'Immunologie, Centre de Recherches du CHUM, , , , Canada
    Immunity 21:757-68. 2004
    ..Our findings reveal a substantial reduction in intrathymic proliferation. The analysis also indicates the existence of a compensatory mechanism acting to sustain the numbers of recent thymic emigrants (RTEs) in the periphery...
  81. ncbi Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL
    Lena Serghides
    Department of Immunology, University of Toronto, Toronto, Ontario, Canada
    J Immunol 175:6368-77. 2005
    ..Thus, OX40L costimulates human antiviral memory CD8 T cell responses largely through indirect effects and can enhance anti-influenza, anti-EBV, and anti-HIV responses, particularly in combination with 4-1BBL or B7...
  82. ncbi A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
    Julian Falutz
    Montreal General Hospital Immuno-Deficiency Treatment Centre, McGill University Health Center, , Quebec, Canada
    AIDS 19:1279-87. 2005
    ..TH9507 may be a beneficial treatment strategy in this population, but longer-term studies with more patients are needed to determine effects on VAT, treatment durability, and safety...
  83. ncbi HHV-8 linked to Kaposi's sarcoma, Castleman's disease and primary effusion lymphoma in a HIV-1-infected man
    Alain Bestawros
    Department of Internal Medicine, Montreal General Hospital and McGill University Health Centre, Montreal, Canada
    J Clin Virol 42:179-81. 2008
  84. ncbi Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease
    Guy Boivin
    Centre Hospitalier Universitaire de Québec CHUQ CHUL and Laval University, Quebec City, Canada
    J Med Virol 68:399-403. 2002
    ..These results suggest that the pathogenesis of the two HHV8-associated diseases (i.e., KS and MCD) might be different, as only the latter was associated with important viremia in our patients...
  85. ncbi The CD4 cell count 3 months after acute retroviral syndrome is associated with the presence of AIDS in the source individual
    Philippe Vanhems
    AIDS 16:2234-6. 2002
  86. ncbi Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age
    Philippe Vanhems
    Laboratoire d épidémiologie et de santé publique, and INSERM Unit 271, Faculte de Medecine, Universite Claude Bernard, et Hôpital Edouard Herriot, Lyon, France
    J Acquir Immune Defic Syndr 31:318-21. 2002
    ..52%, p=.01). Genital ulcerations were present only in cases of sexual exposure to HIV. Injecting drug users had or reported symptoms associated with the ARS less frequently than persons acquiring HIV via sexual transmission...
  87. ncbi Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy
    Heather Leitch
    British Columbia Cancer Agency, Division of Medical Oncology, University of British Columbia, Vancouver, Canada
    HIV Clin Trials 4:107-14. 2003
    ..Discontinuation of chemotherapy in patients receiving PI-based antiretroviral therapy appears to be feasible in patients who attain remission of KS...